Ann: Shareholder Update - Progress and Strategy, page-8

No HTLV-1 update which is due (this was disappointing to not be included)

Dog trials same-same: NZ locking in and planning USA with a May timeline.
Has commenced negotiations with Several major Vet licencees. This is a bit interesting because I was assuming it was almost a one horse race for a while and that horse being Elanco. I guess it is a wait and see thing. I don't think a deal is coming before Ph3.

Funding from MND is agreed but I do not believe it has actually been put in the PAA bank. Well, even so, I understand it is milestone based and as far as I know we have not met the first milestone requirement - pills delivered.

The company must have selected a CRO for Covid - really good news. Site selection underway, good. Omicron is bringing a new wave so that will be interesting. I would think it would be prudent to consider the "already vaccinated" & "already had it" as i understand that the virus is seemingly re-infecting or for the vaccinated, 2 doses is not seemingly cutting it.

Patent (PCT) progress for Covid ongoing. Good, would expect nothing less.

Tablet manufacture in Jan, we knew that.

ONJ work ongoing.. I am not surprised due to the complexity and sheer volumes to work through.

OHD and e-waste was not really informative given how long the grant has been on the table. Not sure what I expected to hear but a bit more that that. I can imagine they have run quite a number of tests, given they tell us the processing is actually relatively quick, and don't doubt the challenges but would have liked to hear that.

So all up, i see a couple of little gems balanced out by gaps in information.

adreamer